ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic

被引：0
作者：
Andrew I. Stolbach
Maryann Mazer-Amirshahi
Ryan Marino
Lewis S. Nelson
Jeremy Sugarman
机构：
[1] Johns Hopkins University School of Medicine,Department of Emergency Medicine
[2] MedStar Washington Hospital Center and Georgetown University School of Medicine,Berman Institute of Bioethics
[3] Case Western Reserve University School of Medicine,undefined
[4] Rutgers New Jersey Medical School,undefined
[5] Johns Hopkins University School of Medicine,undefined
来源：
Journal of Medical Toxicology | 2020年 / 16卷
关键词：
Off-label prescribing; Emergency use authorization; Compassionate use; Expanded access; COVID-19; Coronavirus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：342 / 345
页数：3
相关论文
共 17 条
  • [1] Hingorani AD(2019)Improving the odds of drug development success through human genomics: modelling study Sci Rep 9 18911-179
  • [2] Kuan V(2017)Overview of FDA’s expanded access program for investigational drugs Ther Innov Regul Sci 51 177-undefined
  • [3] Finan C(undefined)undefined undefined undefined undefined-undefined
  • [4] Kruger FA(undefined)undefined undefined undefined undefined-undefined
  • [5] Gaulton A(undefined)undefined undefined undefined undefined-undefined
  • [6] Chopade S(undefined)undefined undefined undefined undefined-undefined
  • [7] Sofat R(undefined)undefined undefined undefined undefined-undefined
  • [8] MacAllister RJ(undefined)undefined undefined undefined undefined-undefined
  • [9] Overington JP(undefined)undefined undefined undefined undefined-undefined
  • [10] Hemingway H(undefined)undefined undefined undefined undefined-undefined
12